NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Rheumatoid Arthritis

Interventions: Methotrexate, Tocilizumab

Countries: France

This multicenter, prospective, non-interventional study is designed to obtain an accurate estimation of the drug retention rate of Tocilizumab (TCZ) Subcutaneously (SC) under real-world conditions in participants with moderate to severe rheumatoid arthritis (RA).

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Participants at least 18 years old
* Participants with moderate to severe RA not previously treated with TCZ (Intravenous \[IV\] or SC) for whom the rheumatologists have decided to initiate TCZ SC treatment as monotherapy or in combination with another conventional synthetic disease modifying anti-rheumatic drugs (csDMARD)

Exclusion Criteria:

* Participants taking part in a clinical trial on RA at the time of inclusion
* Participants with a contra-indication to TCZ SC therapy

Locations (77)

Amiens, France
Aubenas, France
Belfort, France
Berck, France
Besançon, France
Bordeaux, France
Brest, France
Caen, France
Cahors, France
Caluire-et-Cuire, France
Cannes, France
Castelnaudary, France
Chambray-lès-Tours, France
Clamart, France
Clermont-Ferrand, France
Compiègne, France
Contamine-sur-Arve, France
Corbeil-essones, France
Corbeil-Essonnes, France
Créteil, France
Dax, France
Dechy, France
Dole, France
Druex, France
Échirolles, France
Gap, France
Haguenau, France
Haguenau, France
Joué-lès-Tours, France
Juvisy-sur-Orge, France
+ 47 more on CT.gov